Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis

NCT00808977 is registered in ClinicalTrials.gov with Palau Pharma S.L.U. as lead sponsor.

NCT NCT00808977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00808977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis
Lead sponsor
Palau Pharma S.L.U.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
June 30, 2010
Enrollment
80 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis